BRINSUPRI
@brinsupri.com
BRINSUPRI (brensocatib) is FDA-approved for non-cystic fibrosis bronchiectasis in adults and children 12 years and older. See Prescribing and Safety Information.
BRINSUPRI's Company Logos
BRINSUPRI's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#80E679
Pastel Green
128, 230, 121
116, 69, 69
44, 0, 47, 10
#112641
Blue Zodiac
17, 38, 65
214, 59, 16
74, 42, 0, 75
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
About BRINSUPRI
BRINSUPRI, developed by Insmed Incorporated, is a breakthrough prescription medication specifically designed for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adults and children aged 12 and older. As the only approved treatment targeting inflammation caused by neutrophils, BRINSUPRI offers a unique approach to managing this chronic condition, which can lead to lung damage and increased flare-ups. Taken as a once-daily pill, it aims to reduce inflammation and mitigate the risks associated with overactive immune responses.
In addition to its therapeutic benefits, BRINSUPRI includes comprehensive safety information, highlighting important considerations for patients, including potential interactions with other medications and the need for regular dental checkups due to possible side effects. Common adverse reactions may include upper respiratory infections, headaches, and skin issues, among others.
Overall, BRINSUPRI represents a significant advancement in bronchiectasis treatment, offering hope for patients seeking effective management of their condition.
Brand industry
Health
Company type
Suggest company type
Year founded
Suggest founded year
Company size
Suggest company size
